RNA medicines and biotechnology innovation by Arcturus Therapeutics

Arcturus Therapeutics has introduced its next-generation lipid delivery system, LUNAR 2.0, while providing an update on its program targeting OTC deficiency. The announcement was included in a ...

Arcturus Therapeutics presented new research on its ARCT-810 mRNA therapy for ornithine transcarbamylase (OTC) deficiency at the SSIEM 2026 conference. The presentation, delivered by Tope Pedro, ...

Arcturus Therapeutics is gearing up to participate in SSIEM 2026, scheduled for August 25–28, where it plans to present its latest developments in treatments for OTC deficiency and mRNA ...

Arcturus Therapeutics announced its participation in SSIEM 2026, which will take place from August 25 to 28. The company will be available at Booth S11, where it plans to discuss its ongoing ...

Arcturus Therapeutics will participate in the 39th National CF Education Conference, which begins tomorrow. The company invites attendees to visit their table and connect directly with their ...

Arcturus Therapeutics has announced that families are invited to join its upcoming virtual presentations focused on scientific and clinical aspects of rare diseases, including urea cycle disorders ...

Arcturus Therapeutics presented a new research poster at the Society for Inherited Metabolic Disorders (SIMD) 2026 Annual Meeting. The company highlighted its ongoing efforts in developing ...

Arcturus Therapeutics draws attention to a critical gap in cystic fibrosis care, noting that while innovative therapies have transformed treatment for about 90 percent of patients, approximately ...

Arcturus Therapeutics is set to present its latest research on ornithine transcarbamylase (OTC) deficiency at the Society for Inherited Metabolic Disorders (SIMD) 2026 Annual Meeting. The company ...